Introduction to an Animal Model of Neonatal Colitis

The neonatal colitis animal model is an experimental system used to mimic abnormal immune activation and intestinal barrier dysfunction during the early stages of gut development. It is typically established by exposing neonates to low-dose inflammatory stimuli or microbe‑associated factors—such as low‑dose dextran sulfate sodium (DSS), lipopolysaccharide (LPS), or colonization with specific bacteria—during the early postnatal period.

During model construction, neonatal animals, whose intestinal barrier is not yet fully mature, are more susceptible to external stimuli, leading to increased intestinal permeability, release of inflammatory cytokines, and disruption of the immune microenvironment. These changes manifest as delayed weight gain, abnormal intestinal structural development, and mild to moderate enteritis.

Service Advantages of the Aniphe BioLablogical Neonatal Colitis Animal Model Platform

The Aniphe BioLab neonatal colitis animal model platform is centered on its ability to precisely induce inflammation during the early stages of intestinal development and to establish stable intestinal barrier disruption, providing a reliable in vivo model system for investigating the early pathogenic mechanisms of inflammatory bowel disease and evaluating intervention strategies.

	Precise control of the early developmental window In light of the immaturity of the neonatal gut, standardizing the timing of interventions can enhance model consistency.
	The model has high stability. Standardize the induction dose and environmental management to reduce inter‑individual variability and enhance the reproducibility of the enteritis phenotype.
	Pathological features closely resemble those of developmental intestinal inflammation. It can consistently reproduce phenotypes such as impaired intestinal barrier development, elevated inflammatory cytokines, and abnormal intestinal architecture.
	Microbiota and immunity research are highly compatible. It can be used for research on gut microbiota modulation, immune developmental abnormalities, and early susceptibility mechanisms.
	The multidimensional evaluation system has been refined. Systematic assessment is achieved by integrating body weight gain, histopathological findings, and inflammatory markers.

Modeling cycle	1 week
Laboratory animals	Newborn rats/mice
Positive drug	Currently, no unified standard exists; epidermal growth factor (EGF), heparin‑binding EGF, granulocyte colony‑stimulating factor (G‑CSF), probiotics (such as Bifidobacteria), or anti‑TLR4 antibodies are commonly used as positive controls to validate the model’s protective sensitivity.
Application areas	Pathogenesis of neonatal necrotizing enterocolitis (immature intestinal barrier, abnormal bacterial colonization, TLR4‑mediated inflammatory signaling, and hypoxia‑ischemia injury); screening of preventive and therapeutic strategies (probiotics, growth factors, anti‑inflammatory interventions); and research on nutritional approaches and intestinal development.

Establishment of an Animal Model of Neonatal Colitis

In the experimental model, preterm neonatal rats were fed formula milk instead of maternal milk during the early postnatal period to attenuate maternally derived immune protection and alter the gut microbiota colonization environment. Concurrently, intermittent hypoxia and cold‑stress exposures were applied to mimic the adverse effects of perinatal stress on intestinal barrier development. Furthermore, low‑dose lipopolysaccharide (LPS) stimulation was used to activate innate immune responses, thereby inducing intestinal mucosal inflammation and impairing barrier function.

This model consistently exhibits key features such as impaired weight gain, increased intestinal permeability, and upregulated inflammatory cytokines, making it an essential experimental platform for investigating neonatal intestinal developmental disorders, microbiota–immune interactions, and intervention strategies for early‑onset inflammatory bowel disease.